HIV-1 entry inhibitors

AIDS Reviews

Volumn 3, Issue 2, 2001, Pages 89-97

  Dietrich, U ^a  

^a INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

Author keywords

Attachment; CD4; Chemokine receptors; Entry inhibitors; Fusion; HIV 1

Indexed keywords

1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); 3 68 RANTES; 4 [(4 BROMOPHENYL)(ETHOXYIMINO)METHYL] 1' [(2,4 DIMETHYL 3 PYRIDINYL)CARBONYL] 4' METHYL 1,4' BIPIPERIDINE; ALPHA N ACETYLNONA DEXTRO ARGININE AMIDE; ANTIRETROVIRUS AGENT; C 34; C1 C5 RANTES; CD4 ANTIGEN DERIVATIVE; CD4 IMMUNOGLOBULIN G2; CG 64222; CHEMOKINE; CHEMOKINE RECEPTOR; CYANOVIRIN N; ENFUVIRTIDE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; LEUCINE RANTES; METHIONINE RANTES; N (6 AMINOHEXYL)GLYCYL N (3 GUANIDINOPROPYL)GLYCYL N (3 GUANIDINOPROPYL)GLYCYL N BENZYLGLYCYL N (3 GUANIDINOPROPYL)GLYCYL DEXTRO LYSYL DEXTRO LYSYL DEXTRO ARGINYL DEXTRO PROLINAMIDE; N 36; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; N NONANOYL RANTES; POLYANION; POLYCARBOXYLIC ACID DERIVATIVE; POLYSULFATE DERIVATIVE; POLYSULFONIC ACID DERIVATIVE; PRO 2000; T 134; T 140; T 22; T 34; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS FUSION PROTEIN;

ANTIVIRAL ACTIVITY; CELL MEMBRANE; CLINICAL TRIAL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM; DRUG EXPOSURE; DRUG HALF LIFE; DRUG ISOLATION; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG SCREENING; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; NONHUMAN; PHARMACOLOGICAL BLOCKING; RECEPTOR BINDING; REVIEW; STRUCTURE ANALYSIS; TARGET CELL; VACCINATION; VIRUS INHIBITION; VIRUS REPLICATION;

EID: 0035203376     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (103)

1. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society-USA Panel
2. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents
3. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
4. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
5. Antivirals and resistance
6. Conformational changes induced in the envelope glycoproteins of the human and simian immunodeficiency viruses by soluble receptor binding
7. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR5
8. CD4-dependent, antibody-sensitive interactions between HIV-1 and its coreceptor CCR5
9. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody
10. Core structure of gp41 from the HIV envelope glycoprotein
11. Atomic structure of a thermostable subdomain of HIV-1 gp41
12. Atomic structure of the ectodomain from HIV-1 gp41
13. HIV entry and its inhibition
14. The HIV-1 envelope glycoproteins: Fusogens, antigens and immunogens
15. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus
16. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV
17. Chemokine receptors - Future therapeutic targets for HIV?
18. Chemokine receptors as HIV-1 coreceptors: Roles in viral entry, tropism and disease
19. Identification of a major co-receptor for primary isolates of HIV-1
20. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5
21. HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G-protein-coupled receptor
22. Change in coreceptor use correlates with disease progression in HIV-1 infected individuals
23. Activity of dextran sulfate and other polysaccharides against human immunodeficiency virus
24. Inhibitory effect of dextran sulfate and heparin on the replication of human immunodeficiency virus (HIV) in vitro
25. Dextran sulfate suppression of viruses in the HIV-family: Inhibition of virion binding to CD4+ cells
26. Human immunodeficiency virus type 1 attachment to HeLa CD4 cells is CD4-independent and gp120 dependent and requires cell surface heparans
27. Mediation of human immunodeficiency virus type 1 binding by interaction of cell surface heparan sulfate proteoglycans with the V3 region of envelope gp120-gp41
28. Development of resistance of human immunodeficiency virus type 1 to dextran sulfate associated with the emergence of specific mutations in the envelope gp120 glycoprotein
29. Sulfated polysaccharides extracted from sea algae as potential antiviral drugs
30. Enhanced human immunodeficiency virus infection in macrophages by high-molecular-weight dextran sulfate is associated with conformational changes of gp120 and expression of the CCR5 receptor
31. Oral dextran sulfate (UA001) in the treatment of the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex
32. Pharmacokinetics, toxicity, and activity of intravenous dextran sulfate in human immunodeficiency virus infection
33. Dextran sulfate is poorly absorbed after oral administration
34. A placebo-controlled double blind prospective study in healthy female volunteers of dextrin sulfate gel: A novel potential intravaginal virucide
35. In vitro and in vivo evaluations of sodium lauryl sulfate and dextran sulfate as microbicides against herpes simplex and human immunodeficiency viruses
36. Naphthalene sulfonate polymers with CD4-blocking and anti-human immunodeficiency virus type 1 activities
37. Parameters of human immunodeficiency virus infection of human cervical tissue and inhibition by vaginal virucides
38. A phase I study of a novel potential intravaginal microbicide, PRO 2000, in healthy sexually inactive women
39. HIV infection is blocked in vitro by recombinant soluble CD4
40. A soluble CD4 protein selectively inhibits HIV replication and syncytium formation
41. High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates
42. The safety and pharmacokinetics of recombinant soluble CD4 (rCD4) in subjects with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex
43. Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome AIDS and AIDS-related complex
44. Phase I study of continuous-infusion soluble CD4 as a single agent and in combination with oral dideoxyinosine therapy in children with symptomatic human immunodeficiency virus infection
45. Retroviral vectors expressing soluble CD4: A potential gene therapy for AIDS
46. Further evaluation of soluble CD4 as an anti-HIV type 1 gene therapy: Demonstration of protection of primary human peripheral blood lymphocytes from infection by HIV type 1
47. Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates
48. CD4-immunoglobuline G2 protects Hu-PBL-SCID mice against challenge by primary human immunodeficiency virus type 1 isolates
49. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG
50. Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults
51. Multiple antiviral activities of cyanovirin-N: Blocking of human immunodeficiency virus type 1 gp120 interaction with CD4 and coreceptor and inhibition of diverse enveloped viruses
52. Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: Potential applications to microbicide development
53. Cyanovirin-N binds to gp120 to interfere with CD4-dependent human immunodeficiency virus type 1 virion binding, fusion, and infectivity but does not affect the CD4 binding site on gp120 or soluble CD4-induced conformational changes in gp120
54. Cyanovirin-N defines a new class of antiviral agent targeting N-linked, high-mannose glycans in an oligosaccharide-specific manner
55. Chemokines and disease
56. The interleukin-8 receptor family: From chemokines to malaria
57. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells
58. Homozygous defect in HIV-1 coreceptors accounts for resistance of some multiply exposed individuals to HIV-1 infection
59. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene
60. Enhancement of the HIV-1 inhibitory activity of RANTES by modification of the N-terminal region: Dissociation from CCR5 activation
61. Extension of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist
62. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist
63. Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants
64. Amino-terminal truncation of chemokines by CD26/dipeptidyl-peptidase IV. Conversion of RANTES into a potent inhibitor of monocyte chemotaxis and HIV-1 infection
65. HIV blocked by chemokine antagonist
66. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity
67. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5
68. Development of CCR5 antagonists as a new class of anti-HIV therapeutic
69. Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5
70. Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140
71. Monoclonal antibody screening of phage-displayed random peptide library reveals mimotopes of chemokine receptor CCR5: Implications for the tertiary structure of the receptor and for an N-terminal binding site for HIV-1 gp120
72. The lymphocyte chemottractant SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line adapted HIV-1
73. HIV coreceptor down-regulation as antiviral principle: SDF-1α-dependent internalisation of the chemokine receptor CXCR4 contributes to inhibition of HIV replication
74. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1
75. Dissociation of the signalling and antiviral properties of SDF-1-derived small peptides
76. Solution structure and basis for functional activity of stromal cell derived factor 1; Dissociation of CXCR4 activation from binding and inhibition of HIV-1
77. Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant
78. Inhibition of HIV infection by bicyclams, highly potent and specific CXCR4 antagonists
79. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR4 chemokine receptor, in human volunteers
80. Marked increase in anti-HIV activity, as well as inhibitory activity against HIV entry mediated by CXCR4, linked to enhancement of the binding ability of Tachyplesin analogs to CXCR4
81. Inhibitory mechanism of the CXCR4 antagonist T22 against human immunodeficiency virus type 1 infection
82. T134, a small-molecule CXCR4 inhibitor, has no cross-drug resistance with AMD3100, a CXCR4 antagonist with a different structure
83. A low-molecular-weight inhibitor against the chemokine receptor CXCR4: A strong anti-HIV peptide T140
84. Anti-human immunodeficiency virus type 1 activity of an oligocationic compound mediated via gp120 V3 interactions
85. A second target for the peptoid Tat/transactivation response element inhibitor CGP64222: Inhibition of human immunodeficiency virus replication by blocking CXC-chemokine receptor 4-mediated virus entry
86. A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor
87. An inhibitor of the Tat/TAR RNA interaction that effectively suppresses HIV-1 replication
88. The fusion domain of HIV gp41 interacts specifically with heparan sulfate on the T-lymphocyte cell surface
89. Development of HIV entry inhibitors targeted to the coiled-coil regions of gp41
90. A trimeric structural domain of the HIV-1 transmembrane protein
91. Core structure of gp41 from the HIV envelope glycoprotein
92. Capture of an early fusion-active conformation of gp41
93. Atomic structure of a thermo-stable sub-domain of HIV-1 gp41
94. Atomic structure of the ectodomain from HIV-1 gp41
95. Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides
96. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection
97. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry
98. Membrane-anchored peptide inhibits human immunodeficiency virus entry
99. Inhibiting HIV-1 entry: Discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket
100. Effect of amino acid replacements, additions and deletions on the antiviral activity of a peptide derived from the HIV-1 GP41 sequence
101. Strong in vitro synergy between the fusion inhibitor T-20 and the CXCR4 blocker AMD-3100
102. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding
103. Fusion-competent vaccines: Broad neutralization of primary isolates of HIV-1